U.S. Biotech Targets Second-Line Treatment for Pancreatic Cancer, Aiming for $460 Million Cash by 2028

On March 5, Tango Therapeutics, Inc. (Nasdaq: TNGX) reported its fourth-quarter and full-year 2025 financial results and business highlights. The company closed the period with $343.1 million in cash, cash equivalents, and marketable securities (approximately KRW 460 billion), securing development funding through 2028.

Key pipeline milestones include plans to initiate a pivotal trial of its PRMT5 inhibitor bopimetostat in second-line MTAP-deficient pancreatic cancer, a Phase 1/2 combination study with Revolution Medicines’ RAS(ON) inhibitor, and a new collaboration to test bopimetostat alongside Erasca’s pan-RAS molecular glue ERAS-0015. Leadership updates announced the succession of CEO duties from founder Barbara Weber to Malte Peters, the appointment of a Chief Regulatory Officer, and enhancements to the board of directors. For the full year 2025, the company reported a net loss of $106 million (approximately KRW 140 billion).

Under the Erasca collaboration, Tango will evaluate ERAS-0015 plus bopimetostat in Phase 1/2 trials targeting patients with MTAP-deficient pancreatic cancer and RAS-mutant non–small cell lung cancer. Following this announcement, TNGX shares reached an all-time high.

In October 2025, Tango raised about $210 million through a public offering and a private investment in public equity (PIPE) to advance its clinical programs and extend its cash runway through 2028.

Tango Therapeutics is a Nasdaq-listed, clinical-stage U.S. biotech company developing precision oncology therapies that exploit synthetic lethality to target MTAP-deficient tumors. Its strategy of combining PRMT5 inhibitors with RAS-targeted agents to address poor-prognosis solid tumors—such as pancreatic and lung cancers—leverages a mechanism selectively active in MTAP-deleted cancers, an area of brisk competition among global pharma developers.